Recent articles
Here's Why Repligen Rose 33.6% in the First Half of 2020
Investors have come to value the company's resilience in an uncertain year.
Here's Why Guardant Health Dropped 10.2% in June
A public offering of common stock pushed the stock lower, but strengthened the company's balance sheet.
Here's Why Bloom Energy Rose 35.5% in June
Most of the monthly gains were driven by progress in an important collaboration.
Here's Why Arrowhead Pharmaceuticals Stock Jumped 34% in June
The RNAi treatment developer is clawing its way back after a rough start to 2020.
Here's Why BioNTech Gained 34.8% in June
One of the world's leading coronavirus vaccine efforts reported promising progress.
Here's Why Mesoblast Stock Rose Over 18% Today
The Australian biopharma earned an important clearance to treat COVID-19 patients in the United States, which could be a sign of things to come.
Dominion Energy Stock Falls 11.3% After the Atlantic Coast Pipeline Is Axed
The energy giant also agreed to divest its natural gas transmission and storage assets to Berkshire Hathaway. The proceeds will not be used to fund the company's ambitious renewable energy portfolio.
Here's Why Neoleukin Therapeutics Dropped Today
The development-stage drug company announced the pricing of a public offering of common stock.
Is Aerie Pharmaceuticals a Buy?
Wall Street has given the eye-care specialist the cold shoulder in 2020. Is that an opportunity for individual investors?
Is Iovance Biotherapeutics a Buy?
After rumors swirled about a potential acquisition, it now appears the biopharma is transitioning to commercial operations as a standalone company.
Here's Why BioNTech Jumped Today
The German biopharma announced a $250 million private investment.
Here's Why Athersys Stock Is Soaring Today
The stem cell stock jumped after a major Wall Street firm initiated coverage, but there's a catch.
Is Wall Street Wrong About Mesoblast?
The cell therapy developer expects to have clinical data for its COVID-19 treatment soon. Will it deliver a historic success or continue the poor track record of stem cell candidates?
Shares of Renewable Energy Group Slide After Revising Q2 Outlook Lower
The biomass-based diesel leader is suffering from both poor market conditions and embarrassing errors in its previous guidance.
Here's Why Agenus Stock Jumped Higher Today
The development-stage biopharma delivered two encouraging updates.
Silver Stocks Jump as Confirmed COVID-19 Cases Rise
Investors are betting precious metals will prove resilient through the ongoing economic slowdown.
Invitae Surges on $1.4B Acquisition of ArcherDX
The genetic testing company pulled the trigger on its largest acquisition yet.
Here's Why Selecta Biosciences Stock Is Soaring Today
A bullish article is sending shares higher.
Here's Why IDEAYA Biosciences Lost Nearly 23% Today
The development-stage drug developer is selling common stock to raise cash. It's a wise move.
Here's Why PolyMet Mining Is Soaring This Week
The development-stage mining company is one step closer to starting operations at a long-delayed project in Minnesota.